Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

The success of CAR-T cells for treating acute myeloid leukaemia (AML) is hampered by toxicity to normal cells and low CAR-T cell persistence. Here, the authors show that the demethylating compound 5′-Azacitdine increases anti-CD123 CAR-T cell cytotoxicity against AML.

Guardado en:
Detalles Bibliográficos
Autores principales: Nadia El Khawanky, Amy Hughes, Wenbo Yu, Renier Myburgh, Tony Matschulla, Sanaz Taromi, Konrad Aumann, Jade Clarson, Janaki Manoja Vinnakota, Khalid Shoumariyeh, Cornelius Miething, Angel F. Lopez, Michael P. Brown, Justus Duyster, Lutz Hein, Markus G. Manz, Timothy P. Hughes, Deborah L. White, Agnes S. M. Yong, Robert Zeiser
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/fe5a9441efac4b52a10770a66f35954d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The success of CAR-T cells for treating acute myeloid leukaemia (AML) is hampered by toxicity to normal cells and low CAR-T cell persistence. Here, the authors show that the demethylating compound 5′-Azacitdine increases anti-CD123 CAR-T cell cytotoxicity against AML.

Ejemplares similares